2%, respectively) in the elafibranor group compared to placebo—although the differences did not reach statistical significance [ 186 ].
← all excerpts
Consensus statements of the Hellenic Autoimmune Liver Diseases Study Group on the diagnosis and current management of primary biliary cholangitis.
1
—
—